Literature DB >> 32989843

miR-483 is downregulated in pre-eclampsia via targeting insulin-like growth factor 1 (IGF1) and regulates the PI3K/Akt/mTOR pathway of endothelial progenitor cells.

Li Han1, Qing-Qing Luo1, Ming-Gang Peng1, Yang Zhang1, Xiao-Hui Zhu2.   

Abstract

AIM: Pre-eclampsia is a serious pregnancy-specific disease with an incidence of 9.4%. MicroRNAs play a key role in regulating factors in pre-eclampsia, but related research is still limited. This study aims to reveal the role and potential mechanisms of miR-483 in pre-eclampsia.
METHODS: miR-483 was detected in venous blood, umbilical cord blood and placental tissue of pre-eclampsia patients by Real-time Quantitative polymerase chain reaction (qRT-PCR). Insulin-like growth factor (IGF1) and miR-483 were detected by qRT-PCR and western blot in endothelial progenitor cells isolated from fetal umbilical cord blood. miR-483 was overexpressed and inhibited to detect changes of IGF1 and PI3K/Akt/mTOR pathway in endothelial progenitor cells by qRT-PCR and western blot.
RESULTS: miR-483 was downregulated in venous blood, umbilical cord blood and placental tissue of pre-eclampsia patients. In endothelial progenitor cells, overexpression of miR-483 inhibited the expression of IGF1, and inhibition of miR-483 promoted the expression of IGF1. miR-483 regulates the expression of PI3K, Akt, and mTOR in endothelial progenitor cells.
CONCLUSION: miR-483 is downregulated in pre-eclampsia and regulates endothelial progenitor cells by targeting IGF1. miR-483 is a potential alternative for diagnosing and treating pre-eclampsia.
© 2020 Japan Society of Obstetrics and Gynecology.

Entities:  

Keywords:  IGF1; PI3K/Akt/mTOR; miR-483; pre-eclampsia

Mesh:

Substances:

Year:  2020        PMID: 32989843     DOI: 10.1111/jog.14412

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN: 1341-8076            Impact factor:   1.730


  6 in total

1.  Differential circular RNA expression profiles in umbilical cord blood exosomes from preeclampsia patients.

Authors:  Minkai Cao; Juan Wen; Chaozhi Bu; Chunyan Li; Yu Lin; Hong Zhang; Yanfang Gu; Zhonghua Shi; Yan Zhang; Wei Long; Le Zhang
Journal:  BMC Pregnancy Childbirth       Date:  2021-04-15       Impact factor: 3.007

Review 2.  Preeclamptic Women Have Disrupted Placental microRNA Expression at the Time of Preeclampsia Diagnosis: Meta-Analysis.

Authors:  Andja Cirkovic; Dejana Stanisavljevic; Jelena Milin-Lazovic; Nina Rajovic; Vedrana Pavlovic; Ognjen Milicevic; Marko Savic; Jelena Kostic Peric; Natasa Aleksic; Nikola Milic; Tamara Stanisavljevic; Zeljko Mikovic; Vesna Garovic; Natasa Milic
Journal:  Front Bioeng Biotechnol       Date:  2021-12-24

3.  Human placenta-based genome-wide mRNA sequencing to identify TEK/IGF1/CSF1/ANGPT2 as crucial segments in the pathogenesis of pre-eclampsia.

Authors:  Lifeng Wang; Lin Zhang; Yuqin Fan; Yanjie Peng; Dandan Song; Jinfeng Fu; Xietong Wang
Journal:  Front Genet       Date:  2022-09-08       Impact factor: 4.772

Review 4.  Diagnostic biomolecules and combination therapy for pre-eclampsia.

Authors:  Jingqi Qi; Bingbing Wu; Xiuying Chen; Wei Wei; Xudong Yao
Journal:  Reprod Biol Endocrinol       Date:  2022-09-06       Impact factor: 4.982

Review 5.  Roles of noncoding RNAs in preeclampsia.

Authors:  Ningxia Sun; Shiting Qin; Lu Zhang; Shiguo Liu
Journal:  Reprod Biol Endocrinol       Date:  2021-07-02       Impact factor: 5.211

6.  The Impact of Melatonin and NLRP3 Inflammasome on the Expression of microRNAs in Aged Muscle.

Authors:  Ramy Ka Sayed; Marisol Fernández-Ortiz; José Fernández-Martínez; Paula Aranda Martínez; Ana Guerra-Librero; César Rodríguez-Santana; Tomás de Haro; Germaine Escames; Darío Acuña-Castroviejo; Iryna Rusanova
Journal:  Antioxidants (Basel)       Date:  2021-03-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.